Learn about free on-demand learning
Reference our medication guides for helpful information
Make a choice that matters
The best care starts with the best information
Rheumatology advocacy involves several branches of government and various agencies. ACR advocates to Congress, federal agencies, and others by writing or signing on to various policy letters.
ACR Comments to CMS on Physician Fee Schedule 2018 Proposed Rule - 9/11/17
ACR Comments to CMS on Quality Payment Program Proposed Rule - 8/18/17
Coalition Letter on Local Coverage Determination Legislation (S. 794) - 7/11/17
ACR Comments to FDA Oncologic Drugs Advisory Committee - 7/10/17
ACR Response to CMS RFI on Regulatory Relief - 6/13/17
ACR Comments to FDA on Biosimilar Interchangeability Guidance - 5/19/17
ACR Letter on Notice of Information Collection Under OMB Emergency Review: Supplemental Questions for Visa Applicants - 5/18/17
Coalition Letter to Secretary Price on CMMI Reform Principles - 5/16/17
ACR Letter on American Health Care Act - 5/8/17
ACR Comments on McArthur Amendment to AHCA - 4/28/17
ACR Comments on CMS Proposals for Patient Condition Groups and Care Episode Groups - 4/24/17
ACR Letter on H1-B Visas and Physician Workforce - 4/17/17
ACR OP-ED on Workforce Challenges - 4/13/17
Coalition Letter on DXA - 3/24/17
ACR Statement on Congressional Efforts to Lower Specialty Drug Costs - 3/22/17
Coalition Letter to CMS on Physician Payment Programs - 3/21/2017
Coalition Letter on DoD Arthritis Research - 3/17/17
Coalition Letter on Cost Sharing - 3/7/17
ACR Letter to Congress on Healthcare Reform - 2/23/17
ACR Comments on ICER - 2/17/17
Coalition Letter on International Collaboration in Medicine - 2/8/17
Coalition Letter on FY17 NIH Funding - 2/7/17
Coalition Letter on IPAB Repeal - 1/24/17
ACR Letters
ACR Comments on MACRA Final Rule - 12/19/16
ACR Comments on Medicare Physician Fee Schedule Proposed Rule - 9/6/16
ACR Comments to ICER on Open Comment Period - 8/1/16
ACR Comments on MACRA Proposed Rule - 6/24/16
ACR Comments to ICER on Draft Scoping Document - 5/5/16
ACR Comments on CMS Part B Drug Payment Demonstration - 5/5/16
ACR Response to Senate Request for Sovaldi Feedback - 3/4/16
ACR Comments on CMS Episode Groups - 3/1/16
ACR Comments on CMS Quality Measure Development Plan - 3/1/16
ACR Comments to FDA on Quinacrine Compounding - 3/1/16
Coalition Letters
Coalition Letter to CMS on HOPPS Proposed Rule - 9/6/16
Coalition Letter 21st Century Cures Bill - 8/11/16
Coalition Letter to CMS Refinement Panel - 8/23/16
Coalition Letter Sunshine Act and CME - 6/29/16
Coalition Letter MACRA, MIPS, and APMS - 6/24/16
Medicare Program; Revisions to Payment Policies under the Physician Fee Schedule and Other Revisions to Part B for CY 2016; Proposed Rule
Coalition for Health Funding Letter to Appropriators
CDC Arthritis Program Funding FY2016: House Version, Senate Version
Biosimilars Naming Letter: OMB Version, FDA Version
Proposal to CMS to Redefine and Reevaluate E&M Codes
Complex Chemotherapy Administration Code Letter to CMS
Therapy Cap Repeal Letter to Congress
SGR Repeal Letter to Speaker Boehner
Medicare Advantage Capitation Rates, Part C and Part D Payment Policies
Medicare Advantage Narrow Networks to CMS
Medicare Shared Savings Program: Accountable Care Organizations Comment Letter to CMS
Letter of Support; Legislation to Repeal IPAB: House Version, Senate Version
Comment on 21st Century Cures Legislative Package
Support the Protect Continuing Physician Education and Patient Care Act
GME Reform Letter to House Energy and Commerce
Primary Care Per Beneficiary Payments Letter to MedPAC